As KOSPI and KOSDAQ plunged for two consecutive days, selling volume spilled over into biotech growth stocks. ABL Bio, pushed by a broader market risk-off sentiment, recorded a new 52-week low during the session.

On the 29th, KOSPI closed at 5,663.24, down 5.98% from the previous trading day, while KOSDAQ finished trading at 660.66, down 6.40%. In both markets, sidecar mechanism and circuit breakers were triggered in succession for the second day, severely dampening investor sentiment.

Affected by these factors, ABL Bio closed the day at 63,300 won, down 5,500 won (7.99%) from the previous trading day. Trading volume was recorded at 525,161 shares, with a trading value of 33.464 billion won.

The stock opened at 69,000 won and rose to 74,000 won in early trading, but turned downward as the market's decline widened. During the session, it fell to as low as 59,800 won, setting a new 52-week low. Although bargain-hunting buying subsequently flowed in to recover the 60,000-won range, the recovery in the decline was limited.

ABL Bio had also closed at 68,800 won the previous day, down 5.23%. Compared to the closing price of 72,600 won on the 27th, the two-day decline amounts to approximately 12.81%. As selling concentrated over a short period, volatility expanded accordingly.

This weakness is not due to company-specific factors but is more characteristic of a supply-and-demand shock resulting from the simultaneous plunge in KOSPI and KOSDAQ. During periods of significant index volatility, biotech growth stocks, whose valuations are based on expectations for clinical outcomes and technology transfers, can experience relatively greater volatility.

ABL Bio is developing new drug candidates for central nervous system diseases, immuno-oncology therapies, and antibody-drug conjugates (ADCs) based on its proprietary bispecific antibody platform, Grabody. Multiple pipelines are progressing in clinical or preclinical stages both domestically and internationally, making the stock price sensitive to clinical results, development timelines, and changes in partner strategies.

The partial rebound from the intraday low suggests that buying interest emerged at the lowered price level. However, with KOSDAQ market volatility not yet subsiding, it is difficult to conclude that selling pressure has been resolved based solely on a single-day rebound.

[This article was written with the assistance of AI. It is informational material for investment reference based on publicly available market data and does not recommend buying or selling any specific stock. Investment decisions and their consequences are the sole responsibility of the investor.]